Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
29 Feb 24
8-K
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
28 Feb 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Other Events
14 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
12 Dec 23
8-K
Entry into a Material Definitive Agreement
28 Nov 23
8-K
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
8 Nov 23
8-K
Other Events
10 Oct 23
8-K
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
8 Aug 23
Registration and prospectus
S-3ASR
Automatic shelf registration
2 Apr 24
D
$400.21 mm in equity / options / securities to be acquired, sold $400.21 mm, 45 investors
19 Mar 24
S-8
Registration of securities for employees
29 Feb 24
S-3ASR
Automatic shelf registration
28 Feb 24
S-8
Registration of securities for employees
21 Dec 22
424B5
Prospectus supplement for primary offering
16 Dec 22
424B5
Prospectus supplement for primary offering
15 Dec 22
424B5
Prospectus supplement for primary offering
8 Nov 22
S-8
Registration of securities for employees
10 May 22
424B5
Prospectus supplement for primary offering
4 Aug 21
Ownership
4
ARTHUR A LEVIN
22 Apr 24
4
ARTHUR A LEVIN
3 Apr 24
4
Sarah Boyce
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
ARTHUR A LEVIN
21 Mar 24
4
Michael F MacLean
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
ARTHUR A LEVIN
12 Mar 24
4
Sarah Boyce
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24